

## Product Update:

latanoprost 50microgram/mL preservative-free single-dose eye-drops  
(Monopost®) (No: 879/13)

Spectrum Thea Pharmaceuticals Ltd

07 June 2013

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

**latanoprost preservative-free eye-drops (Monopost®)** are accepted for restricted use within NHS Scotland.

**Indication under review:** for the reduction of elevated intraocular pressure in patients with open angle glaucoma and ocular hypertension.

**SMC restriction:** to use in patients who have proven sensitivity to the preservative benzalkonium chloride.

SMC has previously accepted preserved latanoprost eye-drops for use in NHS Scotland. This preparation is substantially more expensive than the equivalent generic multi-dose eye drop preparation with preservative.

### **Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

*This assessment is based on data submitted by the applicant company up to and including 15 April 2013.*

**Chairman,  
Scottish Medicines Consortium**